(ZURA) Zura Bio Ordinary Shares - Overview
Stock: Tibulizumab, Torudokimab, Crebankitug
| Risk 5d forecast | |
|---|---|
| Volatility | 95.7% |
| Relative Tail Risk | -11.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.54 |
| Alpha | 216.06 |
| Character TTM | |
|---|---|
| Beta | 1.515 |
| Beta Downside | 1.521 |
| Drawdowns 3y | |
|---|---|
| Max DD | 97.00% |
| CAGR/Max DD | -0.10 |
Description: ZURA Zura Bio Ordinary Shares December 22, 2025
Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotech focused on novel immunotherapies for immune-mediated and inflammatory diseases in the United States. Founded in 2022 and based in Henderson, Nevada, the company trades as a common stock under the GICS sub-industry “Biotechnology.”
The lead asset, **Tibulizumab**, is a bispecific IgG-scFv antibody that simultaneously blocks IL-17A and BAFF (B-cell activating factor). It is currently in a Phase 2 trial targeting indications such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Zura’s pipeline also includes **Torudokimab (ZB-880)**, an IL-33 neutralizing monoclonal antibody that has completed Phase 1/2 studies, and **Crebankitug (ZB-168)**, an IL-7Rα antagonist that finished Phase 1/1b trials, both aimed at broader inflammatory and autoimmune indications.
Key market-level observations: (1) The U.S. biologics market for autoimmune disorders is projected to grow at a CAGR of ~7% through 2028, driven by rising prevalence of conditions like psoriasis and lupus. (2) Zura reported a cash runway of approximately 12 months as of its latest 10-Q, with R&D expenses accounting for ~45% of total outflows-typical for a company at this stage. (3) Peer-group analysis shows that Phase 2 bispecific antibodies in the IL-17/BAFF space have historically achieved median forward-price multiples of 12×–15× upon successful Phase 3 read-out, indicating a potentially high upside if Tibulizumab meets its efficacy endpoints.
Given the early-stage nature of Zura’s assets and the limited public financial history, investors should treat any valuation as highly speculative and weigh the probability-adjusted return against the company’s cash burn and upcoming trial milestones.
For a deeper, data-driven look at ZURA’s risk-adjusted upside, you might find the analyst tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -62.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA -23.24 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -53.4m > Net Income -62.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (94.6m) vs 12m ago 8.28% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.00% > 50% (prev 0.0%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: -17.77 > 6 (EBITDA TTM -68.9m / Interest Expense TTM -3.88m) |
Altman Z'' -10.70
| A: 0.81 (Total Current Assets 142.3m - Total Current Liabilities 25.5m) / Total Assets 143.9m |
| B: -1.44 (Retained Earnings -207.4m / Total Assets 143.9m) |
| C: -0.41 (EBIT TTM -69.0m / Avg Total Assets 166.5m) |
| D: -8.13 (Book Value of Equity -207.4m / Total Liabilities 25.5m) |
| Altman-Z'' Score: -10.70 = D |
What is the price of ZURA shares?
Over the past week, the price has changed by +5.81%, over one month by +24.43%, over three months by +72.70% and over the past year by +239.55%.
Is ZURA a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZURA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.6 | 159.6% |
| Analysts Target Price | 15.6 | 159.6% |
| ValueRay Target Price | 7.1 | 18% |
ZURA Fundamental Data Overview February 02, 2026
Revenue TTM = 2000 USD
EBIT TTM = -69.0m USD
EBITDA TTM = -68.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -139.0m USD (from netDebt column, last quarter)
Enterprise Value = 230.3m USD (369.3m + (null Debt) - CCE 139.0m)
Interest Coverage Ratio = -17.77 (Ebit TTM -69.0m / Interest Expense TTM -3.88m)
EV/FCF = -4.30x (Enterprise Value 230.3m / FCF TTM -53.5m)
FCF Yield = -23.23% (FCF TTM -53.5m / Enterprise Value 230.3m)
FCF Margin = -2.68m% (FCF TTM -53.5m / Revenue TTM 2000 )
Net Margin = -3.13m% (Net Income TTM -62.5m / Revenue TTM 2000 )
Gross Margin = unknown ((Revenue TTM 2000 - Cost of Revenue TTM 39.0k) / Revenue TTM)
Tobins Q-Ratio = 1.60 (Enterprise Value 230.3m / Total Assets 143.9m)
Interest Expense / Debt = unknown (Interest Expense -3.88m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.5m (EBIT -69.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.58 (Total Current Assets 142.3m / Total Current Liabilities 25.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 2.02 (negative EBITDA) (Net Debt -139.0m / EBITDA -68.9m)
Debt / FCF = 2.60 (negative FCF - burning cash) (Net Debt -139.0m / FCF TTM -53.5m)
Total Stockholder Equity = 129.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.55% (Net Income -62.5m / Total Assets 143.9m)
RoE = -48.17% (Net Income TTM -62.5m / Total Stockholder Equity 129.8m)
RoCE = -58.24% (EBIT -69.0m / Capital Employed (Total Assets 143.9m - Current Liab 25.5m))
RoIC = -41.99% (negative operating profit) (NOPAT -54.5m / Invested Capital 129.8m)
WACC = 11.50% (E(369.3m)/V(369.3m) * Re(11.50%) + (debt-free company))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 41.77%
Fair Price DCF = unknown (Cash Flow -53.5m)
EPS Correlation: -2.63 | EPS CAGR: -2.12% | SUE: 1.33 | # QB: 1
Revenue Correlation: 22.89 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.78 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-2.6% | Growth Revenue=+0.0%